当前位置: 首页 >> 检索结果
1. Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
作者: Anna Meta Dyrvig Kristensen.;Xavier Rossello.;Dan Atar.;Troels Yndigegn.;Takeshi Kimura.;Roberto Latini.;Bertil Lindahl.;Sigrun Halvorsen.;Michael Hecht Olsen.;Valentin Fuster.;Robin Hofmann.;Kjell Vikenes.;Michael Maeng.;David Erlinge.;Stuart Pocock.;Patric Karlström.;Arnhild Bakken.;Theis Lange.;Jose A Barrabés.;Jocelyne Benatar.;Sergio Raposeiras-Roubin.;Claes Held.;Massimo Piepoli.;Morten Wang Fagerland.;Therese Holmager.;Neiko Ozasa.;Eva Irene Bossano Prescott.;John Munkhaugen.;Tomas Jernberg.;Borja Ibanez.; .
来源: N Engl J Med. 2025年
The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear.
2. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.
作者: Luke J Laffin.;Stephen J Nicholls.;Russell S Scott.;Peter M Clifton.;John Baker.;Ashish Sarraju.;Shweta Singh.;Qiuqing Wang.;Kathy Wolski.;Huansheng Xu.;Jen Nielsen.;Naimish Patel.;Jason M Duran.;Steven E Nissen.
来源: N Engl J Med. 2025年
Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides and a decreased lifetime risk of atherosclerotic cardiovascular disease.
3. A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.
作者: Tarik Asselah.;Michael A Chattergoon.;Alina Jucov.;Anca Streinu-Cercel.;Pietro Lampertico.;Heiner Wedemeyer.;Patrick T Kennedy.;Edward J Gane.;Brianna L Bullard.;Sophia Chow.;Desiree Santos.;Gregory Camus.;Yimeng Lu.;Cara Pilowa.;Carey Hwang.;Todd Correll.;Kosh Agarwal.; .
来源: N Engl J Med. 2025年
Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D virus (HDV) infection are unknown.
4. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.
作者: Atul Verma.;David H Birnie.;Chenyang Jiang.;Hein Heidbüchel.;Gerhard Hindricks.;Paulus Kirchhof.;Jeff S Healey.;Yunhe Wang.;Nikolaos Dagres.;Marc W Deyell.;Prashanthan Sanders.;Rajeev K Pathak.;Pieter Koopman.;Dieter Nuyens.;Paul Novak.;Guy Amit.;Charles Dussault.;Bhavanesh Makanjee.;F Russell Quinn.;Umjeet Jolly.;Leon Iden.;Malte Kuniss.;Mukul Sharma.;Andrew Ha.;Vidal Essebag.;Jean Champagne.;Michael D Hill.;Eric E Smith.;George A Wells.; .
来源: N Engl J Med. 2025年
Whether successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy is unknown.
5. Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
作者: Vlado Perkovic.;Hernán Trimarchi.;Vladimir Tesar.;Richard Lafayette.;Muh Geot Wong.;Jonathan Barratt.;Yusuke Suzuki.;Adrian Liew.;Hong Zhang.;Kevin Carroll.;Vivekanand Jha.;Alejandra Quevedo.;Seung Hyeok Han.;Manuel Praga.;Bobby Chacko.;Manisha Sahay.;Chee Kay Cheung.;Laura Kooienga.;Michael Walsh.;Jing Xia.;Cecile Fajardo.;Lokesh Shah.;Jeffrey Hafkin.;Dana V Rizk.; .
来源: N Engl J Med. 2025年
The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and inhibits APRIL.
6. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
作者: Erin A Bohula.;Nicholas A Marston.;Ajay K Bhatia.;Gaetano M De Ferrari.;Lawrence A Leiter.;Jose C Nicolau.;Jeong-Gun Park.;Julia F Kuder.;Sabina A Murphy.;Emileigh Walsh.;Huei Wang.;Vladimir Blaha.;Andrzej Budaj.;Jan H Cornel.;Assen Goudev.;Robert Gabor Kiss.;Alberto J Lorenzatti.;Alexander Parkhomenko.;Marcoli Cyrille.;Gabriel Paiva da Silva Lima.;E Magnus Ohman.;Robert P Giugliano.;Marc S Sabatine.; .
来源: N Engl J Med. 2025年
The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, stroke, or symptomatic peripheral artery disease. The effect of evolocumab on the risk of MACE among patients without a previous myocardial infarction or stroke is unknown.
7. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.
作者: Nicholas A Marston.;Brian A Bergmark.;Veronica J Alexander.;Thomas A Prohaska.;Yu Mi Kang.;Filipe A Moura.;Andre Zimerman.;Elaine Waldman.;Julia Weinland.;Sabina A Murphy.;Erica L Goodrich.;Shuanglu Zhang.;Shuting Xia.;Dan Li.;Anne C Goldberg.;Assen Goudev.;Lina Badimon.;Robert Gabor Kiss.;Michal Vrablik.;Daniel Gaudet.;Philippe Moulin.;Erik S G Stroes.;Maciej Banach.;Hofit Cohen.;Dirk Blom.;Min-Ji Charng.;Børge G Nordestgaard.;Stephen J Nicholls.;Sotirios Tsimikas.;Robert P Giugliano.;Marc S Sabatine.; .
来源: N Engl J Med. 2025年
Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III messenger RNA, have not been established in this population.
8. Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
作者: Seung-Jun Lee.;Hee Tae Yu.;Yong-Joon Lee.;Sang-Hyup Lee.;Jung Ho Heo.;Sung Gyun Ahn.;Sanghoon Shin.;Joon-Hyung Doh.;Ae-Young Her.;Byung-Ryul Cho.;Gwang-Sil Kim.;Taek-Geun Kwon.;Sang-Wook Lim.;Jaemin Shim.;Ji-Yong Jang.;Kyounghoon Lee.;Yun-Hyeong Cho.;Cheol Ung Choi.;Sang-Rok Lee.;Hyung-Bok Park.;Han Cheol Lee.;Seunghwan Kim.;Kyeong Ho Yun.;Jong-Hwa Ahn.;Byoung-Kwon Lee.;Deok-Kyu Cho.;Song-Yi Kim.;Ung Kim.;Tae Soo Kang.;Seong Huan Choi.;Won-Ho Kim.;Jin Bae Lee.;Moo-Yong Rhee.;Jin-Bae Kim.;Sang-Ho Jo.;Dae Woo Hyun.;Daehoon Kim.;Tae-Hoon Kim.;Sung-Jin Hong.;Jae-Sun Uhm.;Dong-Ho Shin.;Chul-Min Ahn.;Byeong-Keuk Kim.;Boyoung Joung.;Young-Guk Ko.;Donghoon Choi.;Myeong-Ki Hong.;Yangsoo Jang.;Hui-Nam Pak.;Jung-Sun Kim.; .
来源: N Engl J Med. 2025年
Despite guideline recommendations, evidence for the use of non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with atrial fibrillation after implantation of a drug-eluting stent remains limited.
9. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
作者: Charmaine E Lok.;Michael Farkouh.;Brenda R Hemmelgarn.;Louise M Moist.;Kevan R Polkinghorne.;George Tomlinson.;Paul Tam.;Marcello Tonelli.;Jacob A Udell.; .
来源: N Engl J Med. 2025年
Cardiovascular disease is the leading cause of death in patients receiving hemodialysis, yet effective preventive therapies remain limited. Supplementation with n-3 polyunsaturated fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may have cardiovascular benefits in the general population, but efficacy among patients receiving hemodialysis is uncertain.
10. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.
作者: Richard Lafayette.;Sean J Barbour.;Robert M Brenner.;Kirk N Campbell.;Tom Doan.;Necmi Eren.;Jürgen Floege.;Vivekanand Jha.;Beom Seok Kim.;Adrian Liew.;Bart Maes.;Atanu Pal.;Roberto Pecoits-Filho.;Richard K S Phoon.;Dana V Rizk.;Hitoshi Suzuki.;Vladimir Tesař.;Hernán Trimarchi.;Xuelian Wei.;Hong Zhang.;Jonathan Barratt.; .
来源: N Engl J Med. 2025年
IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of patients, IgA nephropathy leads to kidney failure or death within 10 to 20 years after diagnosis. Atacicept is a native human transmembrane activator and calcium-modulator and cyclophilin-ligand interactor (TACI)-Fc fusion protein that inhibits two key immunoregulatory cytokines - B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) - that are thought to be central to the pathophysiology of IgA nephropathy.
11. Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.
作者: Elissa Malkin.;Marija Zaric.;Mark Kieh.;Lindsey R Baden.;David Fitz-Patrick.;Arianna Marini.;Heejin Yun.;Peter Hayes.;Rachel Bromell.;Morolayo Ayorinde.;Natalia Fernandez.;Ruhani Varma.;Faith Sigei.;Matthew Ward.;Hema Pindolia.;Shayna Sewell.;Fahimah Amini.;Julie Blie.;Barthalomew Wilson.;Patrick Faley.;John McCullough.;Franklin Tokpah.;Cecelia Wisseh.;Elvis Towalid.;Swapnil Hadawale.;Eddy Sayeed.;Devin Hunt.;Nahid Keshavarzi.;Burc Barin.;Irina Maljkovic Berry.;Christopher L Parks.;Shobhna Gopal Truter.;Kathleen Walker.;Johan Vekemans.;Jennifer Lehrman.;Michelle Engelbrecht.;Mariette Malherbe.;Dagna Laufer.;Vincent Philiponis.;Elizabeth Higgs.;Gaudensia Mutua.;Patricia E Fast.;Swati B Gupta.; .
来源: N Engl J Med. 2025年393卷18期1807-1818页
No vaccine is currently available for Lassa fever, a viral hemorrhagic disease that is estimated to cause thousands of deaths each year in western Africa. A replication-competent recombinant vesicular stomatitis virus-vectored vaccine encoding a Lassa virus (LASV) glycoprotein complex, rVSVΔG-LASV-GPC, has been developed, but data on its safety and immunogenicity are limited.
12. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.
作者: Robert Bissonnette.;Jennifer Soung.;Adelaide A Hebert.;Andrew E Pink.;Andreas Pinter.;Angela Y Moore.;Yuling Shi.;Wen-Hui Wang.;Darryl P Toth.;Megan Miller-Kassamali.;Joseph Cafone.;Jingzhi Jiang.;Shu Li.;Cynthia M C DeKlotz.;Fabio Nunes.;Mark G Lebwohl.
来源: N Engl J Med. 2025年393卷18期1784-1795页
Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis.
13. Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer.
作者: Ian H Kunkler.;Nicola S Russell.;Niall Anderson.;Richard Sainsbury.;J Michael Dixon.;David Cameron.;Juliette Loncaster.;Matthew Hatton.;Helen Westenberg.;Jackie Clarke.;Heather McCarty.;Rhun Evans.;Konstantinos Geropantas.;Virginia Wolstenholme.;Abdulla Alhasso.;Pamela Woodings.;Lisa Barraclough.;Neil Bayman.;Richard Welch.;Fidelis Muturi.;Tracy McEleney.;Jacqueline Burns.;Kathleen Riddle.;Eve Macdonald.;Joanna Dunlop.;Nicole Sergenson.;Geertjan van Tienhoven.;Karen J Taylor.;John M S Bartlett.;Tammy Piper.;Galina Velikova.;Edwin Aird.;Boon Chua.;Coen Hurkmans.;Karen Venables.;Linda J Williams.;Jeremy S Thomas.;Andrew M Hanby.;Marjory Maclennan.;Susan Cleator.;Eldo T Verghese.;Yexiong Li.;Shulian Wang.;Peter Canney.; .; .
来源: N Engl J Med. 2025年393卷18期1771-1783页
The role of postmastectomy chest-wall irradiation in patients with breast cancer classified as pN1 (with involvement of one to three axillary nodes) or pN0 (pathologically node negative) with additional risk factors is uncertain.
14. Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine.
作者: Naina McCann.;Margarete Paganotti Vicentine.;Narges Ebrahimi.;Melanie Greenland.;Brian Angus.;Andrea M Collins.;Thomas Darton.;Katherine Emary.;Saul N Faust.;Amy Flaxman.;Noshi Maria.;Christopher A Green.;Claudia Juarez Molina.;Ravindra Paidisetti.;Rajeka Lazarus.;Grace C Macaulay.;Florence McLean.;V Krishna Mohan.;M Gangadhara Naidu.;Maheshi N Ramasamy.;D Yogeswara Rao.;Nisha Singh.;Sophie Vernon.;Young Chan Kim.;Myron M Levine.;Xinxue Liu.;Andrew J Pollard.; .
来源: N Engl J Med. 2025年393卷17期1704-1714页
Salmonella enterica serovar Paratyphi A (also known as S. Paratyphi A) is responsible for more than 2 million cases of enteric fever annually. There are no licensed vaccines against S. Paratyphi A.
15. A Randomized Trial of Physical Therapy for Meniscal Tear and Knee Pain.
作者: Jeffrey N Katz.;Jamie E Collins.;Leslie Bisson.;Morgan H Jones.;James J Irrgang.;Faith Selzer.;Clare E Safran-Norton.;Kurt P Spindler.;Heidi Y Yang.;Swastina Shrestha.;Kim L Bennell.;James K Sullivan.;Melissa A Kluczynski.;Kaetlyn Arant.;Maame Opare-Addo.;Jamie L Huizinga.;Zoe Zimmerman.;Derek Sople.;Peter Tonsoline.;Madhuri Kale.;William M Wind.;Antonia F Chen.;Michael Freitas.;Bryson Lesniak.;Kelly Jordan.;Elizabeth G Matzkin.;Courtney Dawson.;Lutul Farrow.;Volker Musahl.;John J Leddy.;Scott D Martin.;Elena Losina.
来源: N Engl J Med. 2025年393卷17期1694-1703页
Physical therapy is routinely recommended for knee pain attributed to a degenerative meniscal tear, but its efficacy has not been established.
16. European Study of Prostate Cancer Screening - 23-Year Follow-up.
作者: Monique J Roobol.;Ivo I de Vos.;Marianne Månsson.;Rebecka A Godtman.;Kirsi M Talala.;Elly den Hond.;Vera Nelen.;Arnauld Villers.;Gregoire Poinas.;Maciej Kwiatkowski.;Stephen Wyler.;Franz Recker.;Donella Puliti.;Giuseppe Gorini.;Marco Zappa.;Alvaro Paez.;Marcos Lujan.;Chris H Bangma.;Teuvo Tammela.;Fritz H Schröder.;Sebastiaan Remmers.;Jonas Hugosson.;Anssi Auvinen.; .
来源: N Engl J Med. 2025年393卷17期1669-1680页
The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because deaths from prostate cancer are expected to rise worldwide owing to increased life expectancy and population growth, a final analysis of the long-term outcomes of prostate cancer screening is essential to understanding the benefits and harms of PSA testing.
17. Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
作者: Sara M Tolaney.;Zefei Jiang.;Qingyuan Zhang.;Romualdo Barroso-Sousa.;Yeon Hee Park.;Mothaffar F Rimawi.;Cristina Saura.;Andreas Schneeweiss.;Masakazu Toi.;Yee Soo Chae.;Yasemin Kemal.;Mukesh Chaudhari.;Mehmet A N Şendur.;Toshinari Yamashita.;Monica Casalnuovo.;Michael A Danso.;Jie Liu.;Jagdish Shetty.;Pia Herbolsheimer.;Sibylle Loibl.; .
来源: N Engl J Med. 2025年
Trastuzumab deruxtecan has shown efficacy in patients with previously treated human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer. The efficacy and safety of trastuzumab deruxtecan in patients with no previous therapy for HER2-positive advanced or metastatic breast cancer are unclear.
18. Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026.
作者: Jake Scott.;Michael S Abers.;Harleen K Marwah.;Nicole C McCann.;Eric A Meyerowitz.;Aaron Richterman.;Derek F Fleming.;Elise J Holmes.;Leah E Moat.;Sydney G Redepenning.;Emily A Smith.;Clare J Stoddart.;Maria E Sundaram.;Angela K Ulrich.;Christopher Alba.;Cory J Anderson.;Meredith K Arpey.;Ethan Borre.;Joseph Ladines-Lim.;Angela J Mehr.;Katherine Rich.;Corey Watts.;Nicole E Basta.;Jana Jarolimova.;Rochelle P Walensky.;Caitlin M Dugdale.
来源: N Engl J Med. 2025年
Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization for respiratory viruses during the 2025-2026 season.
19. A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.
作者: Ruth K Lucinde.;Henry Gathuri.;Paul Mwaniki.;Benedict Orindi.;Edwin O Otieno.;Stella Mwakio.;Lillian Mulemi.;Lynda Isaaka.;Jimmy Shangala.;Metrine Saisi.;Elizabeth Isinde.;Irene N Oginga.;Alvin W Wachira.;Evans Manuthu.;Hazel Kariuki.;Patrick Asaava.;Jared Nyikuli.;Cyprian Wekesa.;Amos Otedo.;Hannah Bosire.;Steve B Okoth.;Winston Ongalo.;David M Mukabi.;Wilberforce Lusamba.;Beatrice Muthui.;Isaac Adembesa.;Caroline Mithi.;Mohammed Sood.;Nadia A Aliyan.;Bernard Gituma.;Matiko G Matiko.;Charles A Omondi.;Loice A Ombajo.;Nicholas Kirui.;Lucy Ochola.;Abdirahman I Abdi.;Eunice W Kagucia.;Mike English.;Mainga Hamaluba.;Isabella Ochola-Oyier.;Dorcas Kamuya.;Philip Bejon.;Edwine Barasa.;Ambrose Agweyu.;Samuel Akech.;Anthony O Etyang.
来源: N Engl J Med. 2025年
Adjunctive glucocorticoids may reduce mortality among patients with severe community-acquired pneumonia (CAP) in well-resourced settings. Whether these drugs are beneficial in low-resource settings with limited diagnostic and treatment facilities is unclear.
20. Deferring Arterial Catheterization in Critically Ill Patients with Shock.
作者: Grégoire Muller.;Damien Contou.;Stephan Ehrmann.;Maëlle Martin.;Pascal Andreu.;Toufik Kamel.;Florence Boissier.;Marie-Ange Azais.;Alexandra Monnier.;Sylvie Vimeux.;Amélie Chenal.;Mai-Anh Nay.;Charlotte Salmon Gandonnière.;Jean-Baptiste Lascarrou.;Jean-Baptiste Roudaut.;Gaëtan Plantefève.;Bruno Giraudeau.;Karim Lakhal.;Elsa Tavernier.;Thierry Boulain.; .
来源: N Engl J Med. 2025年
In patients with shock, whether noninvasive blood-pressure monitoring is an effective alternative to the recommended use of an arterial catheter is uncertain.
|